Effect of Teriparatide Versus Zoledronate on Posterior Lumbar Interbody Fusion in Postmenopausal Women with Osteoporosis.

Xiong Y, Li L, Liu P, Zhou B, Kang Y, Wang G

World neurosurgery9 Sept 2022Cited by 8 (Europe PMC)

PMID36096387DOI10.1016/j.wneu.2022.09.021PepBankPUB-36096387

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women after lumbar fusion, teriparatide achieved bony union more frequently than zoledronate at 6 months.
In plain wordsIn women after lumbar fusion, teriparatide produced more bone unions than zoledronate at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBony union at 6 months
Study
n = 77
Comparator
zoledronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Bony union had been achieved more frequently in the teriparatide group than in the zoledronate group at 6 months postoperatively (P < 0.05), although the overall rate of bone union was comparable between the 2 groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis undergoing PLIF for degenerative spondylolisthesis were randomly assigned to receive either zoledronate or teriparatide.
Report a problemFND-3609638701
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women after lumbar fusion, overall bone union rates were comparable with teriparatide and zoledronate.
In plain wordsIn women after lumbar fusion, overall bone union rates were similar with teriparatide and zoledronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOverall bone union
Study
n = 77
Comparator
zoledronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Bony union had been achieved more frequently in the teriparatide group than in the zoledronate group at 6 months postoperatively (P < 0.05), although the overall rate of bone union was comparable between the 2 groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis undergoing PLIF for degenerative spondylolisthesis were randomly assigned to receive either zoledronate or teriparatide.
Report a problemFND-3609638702
03HumanRandomized controlled trialSafety outcome
In women after lumbar fusion, instrumentation-related sequelae were comparable with teriparatide and zoledronate.
In plain wordsIn women after lumbar fusion, instrumentation-related complications were similar with teriparatide and zoledronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeInstrumentation-related sequelae
Study
n = 77
Comparator
zoledronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
sequelae
13.9%
teriparatide
sequelae
22%
zoledronate
Source sentences
Summary
The incidence of instrumentation-related sequelae was also comparable between the 2 groups (teriparatide vs. zoledronate group, 13.9% vs. 22.0%).
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis undergoing PLIF for degenerative spondylolisthesis were randomly assigned to receive either zoledronate or teriparatide.
Report a problemFND-3609638703
04HumanRandomized controlled trialEfficacy outcome
In women after lumbar fusion, teriparatide produced greater BMD increments than zoledronate at 12 months.
In plain wordsIn women after lumbar fusion, teriparatide increased bone density more than zoledronate at 12 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD increments at 12 months
Study
n = 77
Comparator
zoledronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
The teriparatide group had attained more BMD increments at 12 months postoperatively than had the zoledronate group.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis undergoing PLIF for degenerative spondylolisthesis were randomly assigned to receive either zoledronate or teriparatide.
Report a problemFND-3609638705
05HumanRandomized controlled trialEfficacy outcome
In women after lumbar fusion, ODI was lower with teriparatide than zoledronate at 12 months.
In plain wordsIn women after lumbar fusion, disability scores were lower with teriparatide than zoledronate at 12 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseODI at 12 months
Study
n = 77
Comparator
zoledronate
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, the ODI had consistently decreased in both groups with a lower ODI in the teriparatide group than in the zoledronate group at 12 months postoperatively.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis undergoing PLIF for degenerative spondylolisthesis were randomly assigned to receive either zoledronate or teriparatide.
Report a problemFND-3609638706

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women after lumbar fusion, BMD improved significantly in both teriparatide and zoledronate groups at final follow-up.
In plain wordsIn women after lumbar fusion, bone density improved from baseline in both teriparatide and zoledronate groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD at final follow-up
Study
n = 77
Comparator
baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Regarding antiosteoporosis, the BMD values had significantly improved in both groups at the last follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis undergoing PLIF for degenerative spondylolisthesis were randomly assigned to receive either zoledronate or teriparatide.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3609638704
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women after lumbar fusion, ODI consistently decreased in both teriparatide and zoledronate groups.
In plain wordsIn women after lumbar fusion, disability scores decreased over time in both teriparatide and zoledronate groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseODI over time
Study
n = 77
Comparator
baseline
Outcome group
Exercise and physical function · Musculoskeletal
Source sentences
Summary
Furthermore, the ODI had consistently decreased in both groups with a lower ODI in the teriparatide group than in the zoledronate group at 12 months postoperatively.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis undergoing PLIF for degenerative spondylolisthesis were randomly assigned to receive either zoledronate or teriparatide.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3609638707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.